Internal Medicine · Bluffton, IN
NPI
1578507539
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
303 S Main St Ste 300
Bluffton, IN, 46714
Phone (260) 919-3300
Groups this clinician bills Medicare through
Medicare paid, 2024
$52K
781 services
Medicare patients, 2024
404
Average age 80
Drug cost, 2024
$2.6M
30,081 prescriptions
Company payments, 2025
$1,042
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pekkakuzhiyil M Mathew was code 99308 (snf e&m), 183 times for 115 patients. In total Pekkakuzhiyil M Mathew billed 781 services in 30 codes, and Medicare paid $52K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-09-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99308 SNF E&M | Office | 183 | 115 | $51.56 | $9,435 |
| 99305 SNF E&M | Facility | 106 | 96 | $96.68 | $10K |
| 99214 Office E&M - Established | Office | 97 | 55 | $71.75 | $6,960 |
| 99305 SNF E&M | Office | 74 | 71 | $95.29 | $7,052 |
| 99308 SNF E&M | Facility | 39 | 32 | $49.33 | $1,924 |
| 99213 Office E&M - Established | Office | 31 | 20 | $58.55 | $1,815 |
| 90662 Vaccine Product | Office | 29 | 29 | $44.10 | $1,279 |
| G0008 Administration of influenza virus vaccine | Office | 29 | 29 | $30.10 | $873 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 24 | 24 | $120.07 | $2,882 |
| 99309 SNF E&M | Office | 23 | 20 | $68.93 | $1,585 |
| 99348 Home E&M - New and Established | Office | 18 | 13 | $56.96 | $1,025 |
| 99307 SNF E&M | Office | 18 | 13 | $26.40 | $475 |
By year: 2022 $66K for 993 services; 2023 $70K for 984 services; 2024 $52K for 781 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pekkakuzhiyil M Mathew prescribed most often to Medicare patients was Atorvastatin Calcium, with 1,493 prescriptions and refills. In total Pekkakuzhiyil M Mathew wrote 30,081 Medicare prescriptions that cost $2.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 1,493 | 2,891 | 355 | $17K |
| Levothyroxine Sodium Generic | 1,316 | 2,238 | 238 | $17K |
| Amlodipine Besylate Generic | 1,182 | 2,488 | 279 | $9,928 |
| Furosemide Generic | 907 | 1,365 | 200 | $5,990 |
| Pantoprazole Sodium Generic | 862 | 1,429 | 207 | $13K |
| Losartan Potassium Generic | 828 | 1,946 | 214 | $9,377 |
| Gabapentin Generic | 795 | 1,042 | 154 | $12K |
| Eliquis Apixaban | 741 | 907 | 122 | $405K |
| Potassium Chloride Generic | 671 | 1,085 | 169 | $13K |
| Metoprolol Succinate Generic | 657 | 1,190 | 146 | $11K |
| Lisinopril Generic | 517 | 986 | 130 | $4,283 |
| Metformin Hcl Generic | 516 | 1,126 | 131 | $3,562 |
| Tamsulosin Hcl Generic | 481 | 925 | 125 | $7,393 |
| Omeprazole Generic | 466 | 974 | 115 | $8,162 |
| Donepezil Hcl Generic | 422 | 578 | 72 | $8,043 |
Brand drugs: 4,139 claims; generic drugs: 25,730 claims; opioid claims: 619.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pekkakuzhiyil M Mathew $1,042 ($1,042 in general payments such as food, travel and fees) from 22 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $170.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $170 |
| Abbvie Inc. ABBV | 10 | $148 |
| Pfizer Inc. PFE | 5 | $109 |
| Sumitomo Pharma America, Inc. 4506.T | 3 | $61.67 |
| Lilly USA, LLC LLY | 3 | $50.05 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $50.04 |
| GlaxoSmithKline, LLC. GSK | 3 | $48.06 |
| Exact Sciences Corporation EXAS | 2 | $44.82 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 2 | $44.75 |
| Grifols USA, LLC | 2 | $41.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.